Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRL 50481 是一种新型的、选择性的 PDE7 的抑制剂,对 PDE7A,PDE7B,PDE4和 PDE3的 IC50值分别为 0.15,12.1,62 和 490 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 389 | 现货 | ||
10 mg | ¥ 521 | 现货 | ||
25 mg | ¥ 997 | 现货 | ||
50 mg | ¥ 1,843 | 现货 | ||
100 mg | ¥ 2,995 | 现货 |
产品描述 | BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively. |
靶点活性 | PDE7B:12 μM, PDE7A:0.15 μM, PDE3:490 μM, PDE4:62 μM |
体外活性 | BRL-50481 increases the cAMP content (19.1±6.2% of IBMX response at 300 μM) but is considerably less potent. BRL-50481 (30 μM) fails to suppress proliferation by itself but significantly potentiates the effect of rolipram. BRL-50481 (30 μM) has no effect on IL-15-induced proliferation but augments the inhibitory effect of rolipram. Pretreatment (30 min) of human monocytes with BRL-50481 has, by itself, a negligible (~2 to 10%) inhibitory effect on TNFα output at all concentrations tested. BRL-50481 also potentiates the inhibitory effect of PGE2 on LPS-induced TNFα release. BRL-50481 has no significant effect by itself on κB-dependent transcription (5.6±1.9% inhibition at 30 μM) and fails to enhance the effect of rolipram (maximum inhibition, 52.9±2.7%; pIC30 value of 5.33±0.12). BRL-50481 suppresses, in a concentration-dependent manner, LPS-induced TNFα release in monocytes in which PDE7A1 is induced (21.7±1.6% inhibition at 30 μM at the 12-h time point) [2]. |
细胞实验 | MOLT-4 cells in 96-well plates are treated for 30 min with BRL-50481. The cAMP content is then determined by an immuno-specific ELISA. Results are expressed as a percentage of the response affected by 100 μM IBMX[2]. |
分子量 | 244.27 |
分子式 | C9H12N2O4S |
CAS No. | 433695-36-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mg/mL
DMSO: 100 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BRL-50481 433695-36-4 Metabolism PDE inhibit BRL50481 Inhibitor BRL 50481 Phosphodiesterase (PDE) inhibitor